BURLINGAME, Calif.--(BUSINESS WIRE)--Urigen Pharmaceuticals, Inc. (OTCBB: URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders, has appointed Dennis H. Giesing, PhD to serve as the company’s Chief Scientific Officer. “I am very pleased to accept this role and participate in Urigen’s efforts to become a successful specialty pharmaceutical company,” said Dennis Giesing, PhD. “URG101 and URG301 are promising drug candidates and provide a foundation on which we can build a comprehensive urological pipeline.”
